- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02229123
Levetiracetam Treatment of Neonatal Seizures: Safety and Efficacy Phase II Study (LEVNEONAT-1)
February 2, 2024 updated by: University Hospital, Tours
Levetiracetam Efficacy and Safety as First-line Treatment of Neonatal Seizures Occuring in Hypoxic-ischemic Encephalopathy Context
LEVNEONAT is a multicentre French clinical trials with the aim to develop new treatment strategies for the treatment of neonatal seizures using Levetiracetam.
The purpose of this study is to determine the correct dosing, safety and efficacy for intravenous levetiracetam as first line treatment in term newborn babies with seizures in hypoxic-ischemic encephalopathy context.
This new anticonvulsivant drug is a promising treatment for seizures in newborns.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Article Focus
- The principal aim of LEVNEONAT-1 is to determine the levetiracetam optimal dose defined as the highest efficient dose under toxicity restrictions for treating neonatal seizures.
- LEVNEONAT-1 is an open-label, sequential dose-finding study with 3 increasing dose levels of levetiracetam.
Strenghts and limitation of study
- For the first time, levetiracetam will be used as the first-line treatment of neonatal seizures and not as an add-on therapy.
- Statistical model is designed for a rare clinical situation with a sequential adaptive method updating in real time the dose allocation for next patient by using all available data from previous participants.
- The targeted population, i.e. the newborn less than 3 days of life, is particularly sensitive and the written consent of both parents is required before the levetiracetam administration.
Study Type
Interventional
Enrollment (Actual)
18
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Geraldine Favrais, Dr
- Phone Number: 0247474749
- Email: g.favrais@chu-tours.fr
Study Contact Backup
- Name: Estelle Boivin
- Phone Number: 0247474620
- Email: e.boivin@chu-tours.fr
Study Locations
-
-
-
Angers, France, 49000
- Service de réanimation néonatale
-
Lille, France, 59037
- Service de réanimation néonatale
-
Orleans, France, 45100
- Service de réanimation et service néonatale
-
Paris, France, 75012
- Service de réanimation néonatale et pédiatrique
-
Reims, France, 51092
- Service de réanimation néonatale
-
Rennes, France, 35000
- Néonatologie
-
Rouen, France, 76031
- Service de Pédiatrie néonatale et réanimation
-
Tours, France, 37 000
- Service de Néonatologie
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
8 months to 9 months (Child)
Accepts Healthy Volunteers
No
Description
Eligibility Criteria:
- Male or female term baby with gestational age of 36-43 weeks and postnatal age < or= 72 hours
One or more of the following :
- APGAR score < 5 at 5 mins
- Umbilical cord or arterial blood sample (within one hour after birth): pH <7.0 or base deficit > or = 16 mmol/L or lactates > or equal to 11 mmol/L
- Abnormal neurological examination before 6 hours of life
- Suspected clinical or EEG seizures
Inclusion criteria:
- A seizure lasting more than 3 minutes or more than 2 seizures lasting more than 20 seconds on a 1 hour-period on standard EEG recording 4 hours before the levetiracetam loading dose
- Availability of 8 electrode EEG recording
- Written informed consent of both parents or the authorized guardians
- Subscription to social security health insurance are required
Exclusion Criteria:
- Suspected or confirmed brain malformation, inborn error of metabolism, genetic syndrome or major congenital malformation
- Congenital (in utero) infection (TORCH)
- Babies who have received phenobarbital or any other anticonvulsive medication other than a bolus of midazolam for intubation
- Anuria/renal failure defined as serum creatinine > 150 micromol/L
- Seizures secondary to treatable metabolic etiology as hypoglycemia and hypocalcemia
- Corrected QT interval (QTc) greater than 450 milliseconds on the electrocardiogram (ECG) prior to inclusion in the presence or absence of a condition that promotes QT prolongation (hypokalemia, maternal treatment during childbirth or treatment of the child with drugs known to prolong QT),
- Participation to an interventional research study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intravenous levetiracetam
1 loading dose of 30, 40 or 50 mg/kg administered intra-venously.
Maintenance treatment: one intra-venous injection /8h, 8 doses in total for a 3-day treatment.
Maintenance dose corresponds to the loading dose quarter i.e. 7.5, 10 or 12.5 mg/kg.
|
Open-study.
If seizure lasting more than 3 minutes on EEG recording or brief repeated seizures (more or equal to 2 seizures lasting more than 20 seconds on a 1 hour-interval), the loading-dose of LEV allocated to patient is infused followed by the 8 maintenance dose.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Levetiracetam Efficacy on EEG recording
Time Frame: the period just before the LEV loading dose (from 20 min to 3 hours) and the 3 hour time-interval from 1 hour 15 min (T11/4) to 4 hours 15 min (T41/4) after the starting of loading dose infusion (T0)
|
Efficacy has been defined as an 80% reduction of seizure burden on EEG recording.
|
the period just before the LEV loading dose (from 20 min to 3 hours) and the 3 hour time-interval from 1 hour 15 min (T11/4) to 4 hours 15 min (T41/4) after the starting of loading dose infusion (T0)
|
Levetiracetam Short-Term Toxicity
Time Frame: 6 days from the loading dose
|
Short-term toxicity focuses on 4 adverse events potentially attributable to LEV occurring in the 6 days following the loading dose: i) Severe apnoea leading to mechanical ventilation during the 4-hour period following the LEV infusion; ii) Anaphylactic shock occurring during the 30 minutes following the LEV infusion; iii) Toxic epidermic necrosis; iv) Stevens-Jonhson Syndrome.
Short-term toxicity has been designed to trigger quickly a decreasing dose allocation to the next potential participant through a e-CRF alert.
|
6 days from the loading dose
|
Levetiracetam Long-Term Toxicity
Time Frame: 30 days from the loading dose
|
Long-term toxicity includes all the adverse events observed and declared to the pharmacovigilance unit up to the hospital discharge or the 30th day of life at the latest.
|
30 days from the loading dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Levetiracetam Elimination Clearance
Time Frame: at 30 min, 4 hours and 7 hours after the end of loading dose infusion, respectively and at 1 to 3 hours and 12 hours to 18 hours after the last levetiracetam maintenance dose, respectively.
|
The mean values of the elimination clearance and their respective interindividual variability will be estimated.
|
at 30 min, 4 hours and 7 hours after the end of loading dose infusion, respectively and at 1 to 3 hours and 12 hours to 18 hours after the last levetiracetam maintenance dose, respectively.
|
Levetiracetam Distribution Volume
Time Frame: at 30 min, 4 hours and 7 hours after the end of loading dose infusion, respectively and at 1 to 3 hours and 12 hours to 18 hours after the last levetiracetam maintenance dose, respectively.
|
The mean values of distribution volumes and their respective interindividual variability will be estimated.
|
at 30 min, 4 hours and 7 hours after the end of loading dose infusion, respectively and at 1 to 3 hours and 12 hours to 18 hours after the last levetiracetam maintenance dose, respectively.
|
Plasmatic Levetiracetam Maximal Concentration
Time Frame: 30 min, 4 hours and 7 hours after the end of Levetiracetam loading dose infusion
|
Plasmatic Peak Value of Levetiracetam Loading dose will be assessed.
|
30 min, 4 hours and 7 hours after the end of Levetiracetam loading dose infusion
|
Levetiracetam Loading Dose Area under Curve
Time Frame: 30 min, 4 hours and 7 hours after the end of Levetiracetam loading dose infusion
|
ndividual PK parameters will be estimated and used to calculated the AUC corresponding to the loading dose, after the first maintenance dose.
|
30 min, 4 hours and 7 hours after the end of Levetiracetam loading dose infusion
|
Levetiracetam Entire Treatment Area Under Curve
Time Frame: at 30 min, 4 hours and 7 hours after the end of loading dose infusion, respectively and at 1 to 3 hours and 12 hours to 18 hours after the last Levetiracetam maintenance dose, respectively.
|
Individual PK parameters will be estimated and used to calculated the cumulative AUC of the entire treatment.
|
at 30 min, 4 hours and 7 hours after the end of loading dose infusion, respectively and at 1 to 3 hours and 12 hours to 18 hours after the last Levetiracetam maintenance dose, respectively.
|
Seizure recurrence from the Efficacy criteria completion to day 6
Time Frame: from 4h15 after the loading dose to 6 days
|
Clinical or electric seizures recurrence after the efficacy criteria assessment and up to the complete levetiracetam elimination (estimated 5 half-life) will be reported by investigator.
|
from 4h15 after the loading dose to 6 days
|
Levetiracetam Efficacy according to the seizure burden intensity prior to loading dose
Time Frame: after the complete recruting period
|
A new analysis will be performed retrospectively by adjusting the efficacy criteria to the seizure burden on the pre-treatment EEG.
Two subgroups will be considered according to the seizure burden (SB) intensity on the pre-treatment EEG, i.e equal or above to 50% of the EEG recording duration (high SB group) and strictly under 50% of it (low SB group), respectively.
LEV efficacy will be considered positive when a SB reduction of 50% will be observed on the post-treatment EEG recording in the high SB group whereas the reduction of 80% will be still valid for the low SB group.
|
after the complete recruting period
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Chair: Geraldine Favrais, Dr, University Hospital of Tours
- Principal Investigator: Geraldine FAVRAIS, Dr, University Hospital of Tours
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 27, 2018
Primary Completion (Actual)
February 23, 2022
Study Completion (Actual)
February 23, 2022
Study Registration Dates
First Submitted
August 27, 2014
First Submitted That Met QC Criteria
August 28, 2014
First Posted (Estimated)
August 29, 2014
Study Record Updates
Last Update Posted (Actual)
February 5, 2024
Last Update Submitted That Met QC Criteria
February 2, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Signs and Symptoms, Respiratory
- Brain Ischemia
- Hypoxia
- Hypoxia, Brain
- Seizures
- Hypoxia-Ischemia, Brain
- Anticonvulsants
- Nootropic Agents
- Levetiracetam
Other Study ID Numbers
- 2014-000791-26
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neonatal Seizures
-
Richard H. HaasUniversity of California, San Diego; Food and Drug Administration (FDA); UCSF... and other collaboratorsCompletedNeonatal SeizuresUnited States
-
University College CorkUniversity College, London; Wellcome TrustCompletedNeonatal SeizuresUnited Kingdom, Ireland, Netherlands, Sweden
-
Children's Hospital of Fudan UniversitySecond Affiliated Hospital of Wenzhou Medical University; Guangzhou Women and... and other collaboratorsTerminated
-
University of MichiganPatient-Centered Outcomes Research Institute; Massachusetts General Hospital; Children's Hospital of Philadelphia and other collaboratorsCompletedNeonatal SeizuresUnited States
-
University of RochesterTerminated
-
Stephanie Merhar, MDTerminated
-
UCB Biopharma SRLTerminatedElectroencephalographic Neonatal SeizuresBelgium, France, Germany, Ireland, United Kingdom, Czechia, Italy
-
Great Ormond Street Hospital for Children NHS Foundation...Karolinska University Hospital; University College London Hospitals; Helsinki... and other collaboratorsCompletedNeonatal SeizuresUnited Kingdom, Sweden, Ireland, Netherlands
-
Cambridge University Hospitals NHS Foundation TrustNorfolk and Norwich University Hospitals NHS Foundation Trust; Luton and Dunstable... and other collaboratorsRecruitingNeonatal SeizuresUnited Kingdom
-
Cairo UniversityUnknown
Clinical Trials on Intravenous Levetiracetam
-
UCB Japan Co. Ltd.CompletedHealthy VolunteersJapan
-
Johns Hopkins UniversityNational Institute on Aging (NIA)CompletedMild Cognitive Impairment (MCI)United States
-
UCB Pharma SACompleted
-
Odense University HospitalCompleted
-
Richard H. HaasThrasher Research FundCompletedSeizures | Disorder of Fetus or NewbornUnited States
-
UCB Japan Co. Ltd.CompletedEpilepsies, PartialJapan
-
Odense University HospitalCompleted
-
Oslo University HospitalUnknownSubclinical Sleep-Activated Epileptiform Activity | CSWSNorway
-
National Institute of Mental Health (NIMH)CompletedBipolar DisorderUnited States
-
Odense University HospitalCompleted